Market Research Report
Asacol HD (Ulcerative Colitis) - Forecast and Market Analysis to 2022
|Published by||GlobalData||Product code||300496|
|Published||Content info||47 Pages
|Asacol HD (Ulcerative Colitis) - Forecast and Market Analysis to 2022|
|Published: February 28, 2014||Content info: 47 Pages||
This publication has been discontinued on January 18, 2018.
During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.
Asacol made a significant impact in the UC market, mostly thanks to mesalamine's well-known safety profile. In turn, Asacol is considered the gold standard for mesalamine products in all forms (tablets, suppositories, enemas). The active ingredient in Asacol, mesalamine, exerts its function through its anti-inflammatory and immunosuppressive actions as a COX inhibitor, a blocker of T-cell-activating cytokines, an adenosine inducer, and an antibody synthesis inhibitor.